Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma) the most common type of liver cancer. Hepatocellular carcinoma is a primary cancer of the liver and is more common in men than in women.
This page contains content from the copyrighted Wikipedia article "Brivanib alaninate"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
